QPPV.COM KNOWLEDGE ASSESSMENT

Semaglutide: Classification, History, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Semaglutide: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which governance approach best reflects the article’s recommended safety system for semaglutide?

Rely exclusively on individual spontaneous case reports Link case review with medication-error surveillance, product-quality complaints, counterfeiting investigations, literature monitoring, periodic safety reporting and communication of label changes Treat quality complaints as separate from pharmacovigilance in all circumstances Use only crude report counts without medical review

Question 2 of 10 Which information is particularly important in a pregnancy exposure case involving semaglutide?

Only the product’s annual sales Timing relative to conception, last dose, indication, glycaemic control, concomitant medicines and maternal and fetal or neonatal outcomes Only whether the patient experienced constipation The patient’s preferred injection device colour

Question 3 of 10 Which statement correctly distinguishes evidence from SUSTAIN-6 and SELECT?

Both trials evaluated the same population, dose and therapeutic indication SUSTAIN-6 concerned injectable semaglutide in a high-risk type 2 diabetes population, whereas SELECT evaluated 2.4 mg weekly semaglutide in people with established cardiovascular disease and overweight or obesity without diabetes SELECT established cardiovascular benefit for every semaglutide product and dose SUSTAIN-6 was a trial exclusively in people without diabetes

Question 4 of 10 What is the most appropriate interpretation of delayed gastric emptying in a patient scheduled for general anaesthesia or deep sedation?

It has no peri-procedural relevance because semaglutide is not an anaesthetic The clinical team should consider possible residual gastric contents and aspiration risk in accordance with current practice and product information The patient should automatically receive a higher semaglutide dose before the procedure It confirms that the patient has gastroparesis

Question 5 of 10 Which information set would be most useful when evaluating a serious acute kidney injury report associated with semaglutide?

Only the brand name and the patient's age Baseline and follow-up kidney function, gastrointestinal symptoms, oral intake, fluid losses, diuretics, renin–angiotensin system medicines and intercurrent illness Only the patient's weight-loss outcome The patient's preference for injections or tablets

Question 6 of 10 Why should aggregate spontaneous reports for Ozempic, Rybelsus and Wegovy not simply be combined into one crude total?

The products contain unrelated active substances Their routes, doses, indications, populations, co-medications and baseline risks differ, creating important confounding Spontaneous reports are never useful for signal detection Only oral products can generate valid safety reports

Question 7 of 10 Which conclusion about pancreatitis is most consistent with the article?

Any abdominal pain is sufficient to confirm pancreatitis A suspected case should be assessed using chronology, enzymes, imaging and alternative causes such as gallstones, alcohol and hypertriglyceridaemia Pancreatitis can be ruled out if nausea is also present A confirmed case should routinely be managed by restarting semaglutide at a lower dose

Question 8 of 10 Which explanation should generally be considered before attributing apparent lack of weight or glycaemic effect to a biological quality defect?

Insufficient dose or duration, missed doses, administration problems, storage issues, behavioural factors, diagnostic error or individual variability Only the patient's age The assumption that all products contain identical strengths The presence of any gastrointestinal symptom

Question 9 of 10 How should sudden vision loss during semaglutide treatment be handled from a safety perspective?

It should wait for the next routine metabolic review It should be treated as an urgent ophthalmological presentation and assessed for retinal disease and possible NAION It should automatically be classified as diabetic retinopathy caused by semaglutide It should be ignored unless HbA1c is elevated

Question 10 of 10 What is the best pharmacovigilance rationale for documenting every dose-escalation date?

Dose-escalation dates are needed only to calculate commercial demand Adverse effects, particularly gastrointestinal effects, may be temporally concentrated during escalation and exposure persists because of the long half-life Dose escalation has no relationship to tolerability The dates establish that every event is caused by the most recent dose

QPPV.com

Semaglutide: Classification, History, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings